Work

Supplementary Table S2 from Phase I/II Study of the Aurora Kinase A Inhibitor Alisertib and Pembrolizumab in Refractory, Rb-Deficient Head and Neck Squamous Cell Carcinomas

Year: 2025

Type: supplementary-materials

Abstract: Supplementary Table S2. Patient characteristics.

DOI: 10.1158/1078-0432.28332802

Authors: Faye M. Johnson, Madison P. O’Hara, Lacin Yapindi, Peixin Jiang, Hai T. Tran, Alexandre Reuben, Weihong Xiao, Maura L. Gillison, Xiaowen Sun, Alexander Khalaf, J. Jack Lee, Jagannadha K. Sastry, Soma Ghosh

Language: English

Topic: Head and Neck Cancer Studies

Subfield: Otorhinolaryngology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4407109688

Cites:

Cited by:

Related to: 10